Callahan Lab

Research focus

NIH R01 · 2025

Understanding Immunotype, a Novel Biomarker for Checkpoint Blockade Resistance

ABSTRACT An estimated 44% of patients with cancer in the United States are eligible to receive immune checkpoint blockade (ICB). FDA-approved ICB agents include α-PD-1 and α-CTLA-4 antibodies, but the majority of patients do not benefit because their tumors are resistant to these agents. ICB treatment is expensive and may lead to serious toxicity. Prospective identification of patients with ICB-resistant cancers would reduce unnecessary risk and cost and give patients opportunities to seek more appropriate treatment options. To address the unmet need for a peripheral blood biomarker for ICB effectiveness, we performed immune profiling of ICB-treated patients with melanoma, using…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.